NCT02521233View on ClinicalTrials.gov

Efficacy and Safety of Candesartan Associated With Chlorthalidone in Essential Arterial Hypertension Control

PHASE3WithdrawnINTERVENTIONAL
0
Timeline

Start Date

November 30, 2016

Primary Completion Date

May 31, 2017

Study Completion Date

August 31, 2017

Conditions
Essential Arterial Hypertension
Interventions
DRUG

Candesartan + Chlorthalidone (8mg+12,5mg)

DRUG

Candesartan + Chlorthalidone (8 mg + 25 mg)

DRUG

losartan+hydrochlorothiazide

Sponsors

Lead Sponsor

EMS
All Listed Sponsors
lead

EMS

INDUSTRY